Literature DB >> 32314713

[Construction of lentivirus plasmid pCDH-NLRX1 and stable expression of NLRX1 in A549 cells].

Yuhang Dong1, Xiaoxiao Zhang1, Fang Wang1, Qikang Ying1, Yunan Feng1, Rongrong Liu1, Xingan Wu2.   

Abstract

Objective To construct nucleotide-binding oligomerization domain-like receptors family member X1 (NLRX1) lentivirus plasmid and stable NLRX1-overexpressing A549 cell line. Methods Full-length cDNA encoding human NLRX1 was amplified from pCMV3-NLRX1 plasmid and then was inserted into pCDH-CMV-MCS-EF1-Puro vector to obtain NLRX1-overexpressing plasmid pCDH-NLRX1. pCDH-NLRX1 lentivirus particles were obtained by co-transfecting pCDH-NLRX1 with packaging plasmids (pMD2 and pAX2) into HEK293T cells. A549 cells were infected with concentrated pCDH-NLRX1 lentivirus particles and then were screened by puromycin to obtain stable NLRX1-overexpressed A549 cell line. The mRNA transcription and protein expression of NLRX1 were detected by real-time quantitative PCR, Western blot analysis and immunofluorescence. Results The lentivirus plasmid pCDH-NLRX1 was successfully constructed. After pCDH-NLRX1 and packaging plasmids were co-transfected into HEK293T cells, we obtained NLRX1 lentivirus particles with the titer of 1×105 TU/mL. After A549 cells were infected with lentivirus particles and screened by puromycin, a stable over-expression cell line of NLRX1 was obtained. NLRX1 was obviously expressed in the lentivirus-infected A549 cells and its mRNA and protein levels significantly increased. Conclusion NLRX1 lentivirus plasmid and stable NLRX1-overexpressing A549 cell line have been successfully constructed.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32314713

Source DB:  PubMed          Journal:  Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi        ISSN: 1007-8738


  1 in total

1.  Long non-coding RNA (LncRNA) CASC9/microRNA(miR)-590-3p/sine oculis homeobox 1 (SIX1)/NF-κB axis promotes proliferation and migration in breast cancer.

Authors:  Jingzhi Chang; Yuxia Zhang; Xin Ye; Hui Guo; Kun Lu; Qing Liu; Yli Guo
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.